FDA requests removal of Opana ER
The U.S. Food and Drug Administration (FDA) requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the FDA is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks.
This is the first time the FDA has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.
Read the press release here.